(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.09%) $79.07
(0.31%) $1.938
(0.89%) $2 331.60
(0.77%) $26.96
(1.13%) $965.70
(0.00%) $0.933
(-0.04%) $11.03
(-0.09%) $0.798
(0.06%) $93.51
Live Chart Being Loaded With Signals
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions...
Stats | |
---|---|
今日成交量 | 6 886.00 |
平均成交量 | 126 947 |
市值 | 2.21M |
EPS | $0 ( 2024-02-20 ) |
下一个收益日期 | ( $-0.360 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.120 |
ATR14 | $0.00400 (1.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Mento Steven J | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Proehl Gerald T | Buy | 125 000 | Stock Option (right to buy) |
2024-01-04 | Fisher Mary | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Scott Kathleen D. | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-04 | Sandler Andrew Seth | Buy | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 8 169 572 | Sell: 872 238 |
Dermata Therapeutics, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.67 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.67 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-13.92 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.43 |
Financial Reports:
No articles found.
Dermata Therapeutics,
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。